-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-510898-24-00
4
2022-01-14
Patients with well differentiated neuroendocrine neoplasia (NENs) not
-
2024-513820-40-00
4
2021-10-29
Metastatic or locally advanced leiomyosarcoma
-
2023-505163-37-00
3
2021-10-01
Metastatic Colorectal Cancer
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-514988-25-00
9
2021-03-31
Cancer
-
2024-514992-16-00
9
2021-03-31
Cancer
-
2024-514993-38-00
9
2021-03-31
Cancer
-
2024-512493-98-00
4
2021-03-25
Glioblastoma
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-516649-38-00
5
2020-12-01
Recurrent ovarian, fallopian tube or primary peritoneal cancer
-
2024-516659-41-00
4
2020-10-12
high-risk, surgically resectable BRAF mutated and wild-type Melanoma
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2024-517200-10-00
4
2020-01-31
Advanced non-small-cell lung cancer
-
2023-510251-31-00
4
2019-12-12
neuroendocrine tumors
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2024-513372-18-00
4
2019-10-18
Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2024-515686-34-00
4
2018-11-16
BRCA-related metastatic breast cancer
-
2024-516221-31-00
4
2016-04-19
Stage IV colorectal cancer
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)